Cartesian Therapeutics Inc (RNAC) financials
Cartesian Therapeutics revenue and earnings by year
Cartesian Therapeutics's revenue was $2.80 million in the fiscal year to December 31, 2025, down 92.8% from the year before. Net income was -$130 million, -4658.6% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 11.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 39 | 26 | 111 | 85 | 17 | 7 | 1 | 0 | 8 |
| Revenue growth | -92.8% | 49.6% | -76.5% | 30.2% | 412.6% | 148.6% | 639.4% | 336.2% | -97.4% | — |
| Operating income | -143 | -44 | -86 | 15 | -5 | -57 | -52 | -65 | -64 | -35 |
| Operating margin | -5127.1% | -112.8% | -332.3% | 13.1% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -428.9% |
| Net income | -130 | -77 | -220 | 35 | -26 | -69 | -55 | -65 | -65 | -36 |
| Net margin | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -448.0% |
| Diluted EPS | -$5.02 | -$4.49 | -$49.76 | — | -$6.60 | — | — | — | — | — |
| Free cash flow | -79 | -32 | -51 | -33 | -61 | 34 | -52 | -60 | -53 | -20 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RNAC in Markets.
See also: RNAC returns
No forecast, no recommendation. This page describes Cartesian Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.